$18.96 0.37 (+1.96%)
2/13/2012 10:17 AM

Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Featured Broker Partners


Advertisement